Metabolomics Services Market is Driven by Growing Pharmaceutical Industry One of the key drivers for the Metabolomics Services Market Growth is pharmaceutical industry. Metabolomics finds wide usage in drug discovery, drug development and clinical trials. It helps to study drug metabolism. Countries in Eastern Europe which are directly impacted by the war are witnessing decreased demand for metabolomics services. The Metabolomics Services Market Size and Trends still remains an important tool for research in applications like disease diagnosis, drug discovery, toxicology, etc. Get More Insights: Metabolomics Services Market (https://medium.com/@avantika.cmi/metabolomics-services-market-is-estimated-to-witness-high-growth-owing-to-innovations-in-mass-c7691b51ed54 )

Calcium Lactate Market Poised for Robust Growth Increasing Application in Pharmaceutical Industry: Calcium Lactate Market Growth is gaining wider application in pharmaceutical formulations due to its pH buffering, nutrient and preservative properties. Expanding Applications in Nutraceuticals: Calcium lactate provides an opportunity for nutraceutical applications owing to its nutritional and pH balancing properties. It can be incorporated in calcium and minerals supplements. The COVID-19 pandemic has negatively impacted the growth of Calcium Lactate Market Size and Trends globally. Lockdowns and restrictions imposed by various governments disrupted the supply chain and logistics, creating a shortage of raw materials. Get More Insights: Calcium Lactate Market (https://www.trendingwebwire.com/calcium-lactate-market-size-and-share-analysis/ )

Modular Construction – Retrofitting Conventional Buildings Shifting construction away from traditional sites and into factories could dramatically change the way we build. Will off-site builds bolster construction this time around? Over the years, construction has straggled behind other sectors in terms of efficiency. Off-site builds or modular construction is a powerful way to reform construction business saving more time, labor, cost and productivity mutually benefitting the manufacturer as well as the customer. What is Modular Construction? Modular Construction is a process in which different components known as Modules are constructed in a controlled factory setting and later assembled on the desired site as per the requirement of the user. In general, 60% to 90% of the work is completed offsite while the rest on the location where the facility is needed. The factory-made, standard modules are accustomed with walls, doors, ceilings, frames, and windows. Additionally, the modules can be integrated with more specific components, such as air handling units, fan filter units, air showers along with the lighting and plumbing facility intended for pharmaceutical use. It is worth mentioning, majority of the modular facilities built are GMP certified ensuring required quality standards have been met while construction. Types of Modular Construction Modular Construction can be broadly categorized into two categories, namely permanent and relocatable. Permanent modular builds mean the facilities are constructed to be used at the same location wherein it has been assembled. In other words, the building is similar to conventionally constructed infrastructure except the fact it has been built off-site. Need for Modular Facilities Conventional construction has never shown to surpass 80% mark owing to factors including logistical delays, type of material used, method of construction adopted and shortage of manpower eventually hampering the productivity. Whereas prefabricated approaches have reported to increase productivity by more than 100%. Modular construction acts as a sustainable method empowering today’s construction sector. The Modular Construction Process In the first phase, a description of the building that is to be constructed is created through discussion between the customer and modular building manufacturer followed by review of the engineering department to evaluate whether the proposed design meets all the applicable building codes. Then, granting of building permit is required in most jurisdictions for constructing new structures, or performing major renovations. Modular Construction in Pharmaceutical Industry The concept of modular construction has been used in other industries for a long time; however, over the past two to three decades, it has only gained significant attention within the pharmaceutical industry. Moreover, there is immense pressure on drug manufacturers to market novel drugs as soon as possible, before patent expiry. Increased pressure to expedite time to market, coupled with the need to decrease operating costs and increase manufacturing efficiencies, have amplified the value of smaller production facilities, which are more efficient and flexible. The modular construction market developments have made modular facilities more attractive to drug manufacturers today, as these facilities can quickly switch between multiple drugs, enabling formulation and packaging in multiple formats, such as solid, liquid, semi-solid and parenteral dosage forms. Roadblocks to Headway It is evident that shifting from conventional on-site construction to off-site modular construction can fundamentally avoid unforeseeable risks. However, on the other hand, construction of modular facilities may face certain challenges, in order to maintain the essentials of design and equipment of the facility. Some of the challenges with this approach may involve factors, such as logistics constraints, transportation, safety permits and communication barriers. For additional details, please visit https://www.rootsanalysis.com/blog/modular-construction-in-pharma-industry/ You may also be interested in the following titles: 1. Smart Labels Market: Industry Trends and Global Forecasts, 2022-2035 2. AI-based Digital Pathology / AI Pathology Market: Industry Trends and Global Forecasts, 2022-2035 About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com

Long-Acting Drug Delivery: A Novel Pharmacological Strategy to Deliver Therapeutic Modalities LADD has emerged as the novel and advanced drug delivery system which manipulate the dosing regimen of the drug in the body in order to sustain its therapeutic level. Over the last two decades, the pharmaceutical industry has observed a paradigm shift from conventional drug delivery strategies to the long-acting drug delivery (LADD) of products to treat several disease indications, such as ophthalmic disorders, oncological disorders, neurological disorders and infectious diseases. These novel systems circumvent the limitations of conventional drug delivery system, such as multiple dosing frequency, fluctuating plasma levels, high toxicity levels and poor patient compliance. Principles and Strategies associated with Long-Acting Drug Delivery Lately, many technologies are being explored to develop long-acting drug in various dosage formats, such as long-acting injectables, depot injections, implantable devices and combination products. The LADD technologies have come a long way with the inclusion of liposomes, microspheres and polymers for the fabrication of biodegradable and biocompatible delivery system. Apart from this, the interdependency of drug, excipient and release environment plays a crucial role to decide the release kinetics of the drug. What are the Benefits of Outsourcing to Contract Service Providers (CDMOs / CDOs / CMOs)? One of the critical factors associated with the development of long-acting drugs is the selection of drug therapeutic window and its absorption characteristics. It also encompasses the quantitative determination of drug metabolism and pharmacokinetic (DMPK) properties. In addition, the formulation of these drugs is a complex process, especially if there is inclusion of highly potent molecules. Some of the other challenges include aseptic manufacturing, terminal sterilization, suitable characterization methods, lack of GMP-certified facilities and specialized equipment. Owing to the advanced LADD technologies, formulation and developmental challenges associated with these complex dosage forms, the reliability on stakeholders having the expertise in this domain has upsurged. This will eventually aid the drug developers to address the bottlenecks stemming from conventional treatment options and improve the clinical outcome. Bottom Line Keeping every trend in mind, Roots Analysis has provided complete information on market trends in long-acting drug delivery domain, which has some of the very recent and precise activities listed for the clients to help them make better decisions in its report titled, Long-Acting Drug Delivery Technologies and Services Market, 2023-2035. To find answers to key decision-making question and to know further about the market forecast analysis, highlighting the likely growth of the long-acting drug delivery technologies and services market, for the time period 2023-2035. For additional details, please visit https://www.rootsanalysis.com/blog/long-acting-drug-delivery-technologies/ You may also be interested in the following titles: 1. Smart Labels Market: Industry Trends and Global Forecasts, 2022-2035 2. AI-based Digital Pathology / AI Pathology Market: Industry Trends and Global Forecasts, 2022-2035 About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com

Demand for Outsourcing Biologics Fill Finish Services The increasing demand for biologics has led to an increasing need for production capacity, which is characterized by high quality standards. Although, it is a challenging field, outsourcing has emerged as a promising segment, especially for drug product manufacturing and aseptic fill / finish operations. Despite being one of the crucial steps of all the steps involved in the production of biologics, fill finish is heavily outsourced activities in the pharmaceutical industry. Currently, it is estimated that more than 50% of the overall operations are outsourced to service providers. Service providers offering these services are using vials for filling of biologics. Of these, over 70% of service providers operate at clinical and commercial scales of operation. Of the players offering these services for biologics are headquartered in Asia-Pacific. More than 35% of these players are located in China. Further, of these, more than 40% players are well established players. Expansions have been witnessed by the industry, since 2013 to cater to the increasing need of their clients; of these, 55% expansions are associated with the establishment of new facility or adding area to the existing facility. Of global biologic fill finish capacity available in the facilities established by services providers is for filling of vials. Further, majority of capacity is available with service providers headquartered in Asia-Pacific. As projected by Roots Analysis, antibodies will have the highest share in this market. This trend is likely to continue in the future. In addition, majority of the market is likely to be driven by the filling of vials and syringes. More than 35% of these service providers are headquartered in Europe. Over 20% of these players were established before 1960 and 45% of the players were established after 2000. With outsourcing being increasingly accepted as a viable / beneficial business model and the anticipated growth in the biologics market, the opportunity for fill finish biopharmaceuticals service providers is expected to grow at a steady pace over the coming years. For additional details, please visit https://www.rootsanalysis.com/blog/demand-for-outsourcing-biologics-fill-finish/ You may also be interested in the following titles: 1. Smart Labels Market: Industry Trends and Global Forecasts, 2022-2035 2. AI-based Digital Pathology / AI Pathology Market: Industry Trends and Global Forecasts, 2022-2035 About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com

mRNA Synthesis: Manufacturing Process of Modern Revolutionary Molecule Messenger ribonucleic acid (mRNA) is a single-stranded molecule, which carries coding sequence and plays a prominent role in protein synthesis. It transfers genetic information form to DNA to ribosomes, a specialized structure, or organelle, which decodes genetic information into a protein. Structure of mRNA Post the onset of the COVID-19 pandemic mRNA has emerged as promising therapeutic tool in modern healthcare industry. With the help of genetic engineering, synthetic mRNAs can express proteins, as they structurally resemble a natural mRNA. Presently, more than 195 mRNA therapeutics / mRNA vaccines are under development or commercialized for the treatment of a variety of indications. As a result, there is an evident increase in the demand for mRNA manufacturing capacity. Application of Synthetic mRNA Several studies conducted by healthcare companies and research institutions have demonstrated the potential of mRNA. Contract Manufacturing in mRNA Synthesis AND Manufacturing Service Domain The synthesis and manufacturing process of mRNA-based therapeutics / vaccines is complex and associated with several challenges. The production of such drug products requires skilled labor, stringent manufacturing protocols and specialized expertise. Further, the biggest challenge in this domain is the purification which involve the use of hazardous solvents / materials and stability of drug products (thereby, requiring specialized facilities and cold chain transportation). Additionally, they also require appropriate drug delivery systems to efficiently administer the intervention (in a manner that they can avoid degradation by cellular endonucleases). However, because of such operational and technical challenges associated with the production of RNA-based products innovators in the biopharmaceutical industry are increasingly relying on the contract service providers. Players Engaged in mRNA Synthesis and Manufacturing Domain Presently, mRNA synthesis and manufacturing service providers landscape features a mix of over 70 large, mid-sized and small companies, which claim to have the required expertise to offer various services for the synthesis and manufacturing of mRNAs across different scales of operations, worldwide. In addition to this, more than 95 mRNA synthesis kits, that contain reagents for the synthesis of research grade mRNAs, are currently available in the market. Recent developments in this segment of the biopharmaceutical industry indicate that the service providers are upgrading their capabilities and infrastructure to accommodate the current and anticipated demand for this novel class of biologics. Concluding Remarks Currently, dozens of preclinical and clinical reports demonstrating the efficacy of these platforms have been published in the last two years alone. However, owing to the several challenges associated with the production of mRNA-based therapeutics / vaccines, majority of the pharmaceutical companies prefer to outsource their manufacturing operations. In the foreseen future, as more of such RNA-based leads mature and move into the clinic and / or get commercialized, we anticipate the mRNA synthesis market to witness healthy growth. For additional details, please visit https://www.rootsanalysis.com/blog/mrna-synthesis-and-manufacturing/ or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Smart Labels Market: Industry Trends and Global Forecasts, 2022-2035 2. 4D Bioprinting Market : Industry Trends and Global Forecasts, 2022-2035 About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com

Viral Clearance and Viral Testing Services Considering the rising demand for biologics, innovators in the biopharmaceutical industry are constantly exploring avenues that would enable them to overcome the existing technical and operational challenges related to viral-clearance and testing for timely approval of biologics. Outsourcing the viral clearance and viral testing studies has emerged as a promising alternative for most of the manufacturers. Despite being one of the crucial steps amongst all the steps involved in the production of biologics, this service is heavily outsourced in the biopharmaceutical industry. Currently, it is estimated that more than 70% of these services are employed by biopharmaceutical and pharmaceutical companies. Service providers across the globe offering this service are large players. Of these, close to 80% players provide services for both, viral clearance and viral testing of different type of biologics. Of the players have established their facilities in Europe. Within this region, UK has the maximum number of facilities (over 21%), followed by Germany (more than 15%) and France (close to 10%). Patents have been filed / granted over last few years. Of these, over 40% patents are granted by organizations headquartered in the US whereas close to 25% patent applications are filed by organizations headquartered in China. As projected by Roots Analysis, more than 55% of the share is captured by viral removal, in the viral clearance market. As projected by Roots Analysis, 40% of the share is captured by North America, in this market. Driven by the rising interest in research and development activities and the demand for the viral clearance and viral testing services, the future opportunities and growth associated with this market are anticipated to witness a noteworthy growth in the foreseen future. Specifically, in terms of end-users, the market is anticipated to be driven by biotechnology and pharmaceutical industry. For additional details, please visit https://www.rootsanalysis.com/blog/viral-clearance-and-viral-testing-services/ or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Smart Labels Market: Industry Trends and Global Forecasts, 2022-2035 2. 4D Bioprinting Market : Industry Trends and Global Forecasts, 2022-2035 About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com

CAR-T Cell Therapies: Addressing Key Unmet Needs Across Various Oncological Indications Amidst the active initiatives undertaken to develop more targeted anti-cancer therapies, CAR-T therapies have emerged as a promising option, given their ability to eradicate tumor cells from the body with minimal treatment-related side effects. Further, CAR-T cell therapies, relatively recent addition to the gamut of anticancer interventions, has demonstrated significant promise. Overall, this highly specific and promising form of CAR-T cell therapy treatment, which harnesses the versatile effector machinery of the human immune system, has revolutionized cancer treatment, globally. Given the consistent increase in number of cell therapies being developed and launched, this upcoming therapeutic segment is on its way to becoming one of the highest valued markets within the biopharmaceutical industry. Over 6,500 patents related to CAR-T cell therapies have been recently filed / granted, demonstrating the continued innovation in this domain. In addition, more than 260 collaborations have been inked between several industry / academic stakeholders in order to advance the development of various pipeline candidates. To fund product development initiatives, capital investments worth more than USD 24 billion have been made by various private and public sector investors, in the last few years. Driven by the ongoing pace of innovation in this field, sufficient financial support from investors and encouraging clinical trial results, the CAR-T cell therapies market is likely to witness significant growth in the foreseen future. A Rise In Partnerships, In The Recent Past, Involving Both International And Indigenous Stakeholders, Validate The Growing Interest In This Domain; Maximum Number Of Such Deals Were Signed In 2021 Since 2015, the partnership activity in this domain has increased significantly. Given that most of the products are commercially available, in recent years, numerous agreements for product evaluation have been inked. Majority of partnerships are licensing agreements followed by R&D agreements (21%); most of the licensing deals (68%) are focused on technology licensing for the development of CAR-T therapies. Several Investors, Having Realized the Opportunity Within This Upcoming Segment, Have Invested Close To USD 25 Billion More than 65% of the total funding amount was invested in the last five years. Specifically, in 2022 so far, companies engaged in this domain have collectively raised more than USD 7 Billion, majority of the funding was acquired through venture capital rounds, other equity financing elements and secondary offerings. Over 6,500 Patents Related to Car-T Therapies Have Been Recently Filed / Granted, Demonstrating The Continued Innovation In This Domain Majority of the patents related to CAR-T cell therapies have been filed by non-industry players; more than 1,400 such patents were filed in 2021 alone. Additionally, most of the patents in this domain are patent applications (84%), followed by granted patents (13%) and Others (3%). The Projected Opportunity for Car-T Cell Therapies Is Likely to Be Well Distributed Across Different Segments And Is Estimated To Grow At An Annualized Rate Of 20%, Till 2035 The global CAR-T cell therapy market is estimated to be worth USD XX billion in 2022, and this value is projected to reach around USD XX billion in 2035, growing at a CAGR of 20%, during the period 2022-2035. In the long-term, the overall projected opportunity is likely to be well distributed across key market segments, including target indications, target antigen, key players and geographical regions. For additional details, please visit https://www.rootsanalysis.com/blog/car-t-cell-therapies-addressing-key-unmet/ or email sales@rootsanalysis.com You may also be interested in the following titles: 1. 4D Bioprinting Market, 2023-2035 2. Non-Viral / Intracellular Drug Delivery Systems Market, 2023-2035 About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com

The mRNA synthesis and manufacturing market is projected to be worth USD 1.5 billion by 2035, claims Roots Analysis Given the current technical and operational challenges associated with the manufacturing of mRNA-based products, innovators in the biopharmaceutical industry are increasingly relying on the mRNA synthesis and contract manufacturing service providers. Roots Analysis has announced the addition of “mRNA Synthesis and Manufacturing Services Market (2nd Edition), 2022–2035” report to its list of offerings. Owing to the recent success and growing pipeline of mRNA-based products in the market, mRNA, as a therapeutic agent, has gained significant traction from the medical community. However, due to challenges, such as high capital requirement, stringent regulations and lack of technical expertise, outsourcing has become a preferred business model and CMOs are upgrading their existing capabilities and service portfolios to meet the increased demand for mRNA-based products. To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/mrna-synthesis-and-manufacturing-market/request-sample.html Key Market Insights Presently, 30+ companies claim to offer custom synthesis services for mRNA, globally. Majority of the service providers are mid-sized players (44%), followed by small (35%), large (12%) and very large players (9%). Additionally, more than 25% of the stakeholders were established post 2010. It is also worth mentioning that over 50% of the total players are based in North America, specifically in the US. More than 40 companies, across the globe, claim to provide contract manufacturing and fill / finish services for mRNA vaccines / therapeutics. Of the aforementioned players, nearly 85% of the contract manufacturing service providers are based in North America and Europe. Notably, more than 50% of the total players engaged in this space offer services for drug substance (APIs) manufacturing. Currently, more than 95 mRNA synthesis kits are available in the market. Close to 70% of the mRNA synthesis kits contain capping enzymes; of these, 96% use T7 RNA polymerase enzyme mix for the synthesis of modified mRNAs. It is worth highlighting that majority (54%) of the kit developers are small players. More than 170 clinical trials have been registered for the evaluation of mRNA-based therapeutics / vaccines, worldwide. The clinical research activity, in terms of number of trials registered, is reported to have increased at a steady CAGR of 44%, during the period 2017-2022. Of the total number of trials registered, close to 22% have already been completed, while 46% of the studies are actively recruiting participants. Partnership activity within this domain has grown at a CAGR of 60%, between 2019 and 2022. Nearly 34% of the deals were inked in 2021. Majority of the instances captured in the report were manufacturing agreements, representing 22% of the total partnerships. Further, most of the intercontinental deals have been inked by players based in North America. North America and Europe are anticipated to capture close to 65% of the global market share, by 2035. The market in Asia Pacific is likely to grow at the highest CAGR during the period 2022-2035. In terms of type of product, drug substance (APIs) is expected to occupy a larger share (70%) of the overall mRNA synthesis and manufacturing service market in 2035. For additional details, please visit https://www.rootsanalysis.com/reports/mrna-synthesis-and-manufacturing-market.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Smart Labels Market: Industry Trends and Global Forecasts, 2022-2035 2. AI-based Digital Pathology / AI Pathology Market: Industry Trends and Global Forecasts, 2022-2035 About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com

LONG-ACTING DRUG DELIVERY TECHNOLOGIES AND SERVICES Long-acting drug delivery has emerged as the novel and advanced drug delivery system which manipulate the dosing regimen of the drug in the body in order to sustain its therapeutic level. Over the last two decades, the pharmaceutical industry has observed a paradigm shift from conventional drug delivery strategies to the long-acting drug delivery of products to treat several disease indications, such as ophthalmic disorders, oncological disorders, neurological disorders and infectious diseases. The long-acting delivery of drug candidates confers several advantages, such as improved patient compliance, reduced dosage requirement, better medication adherence, decrease in failure risk due to inconsistent usage and more convenience to patients. In addition, long acting drug delivery formulations can improve the chemical stability, solubility and polymorphic transformation issues of the active pharmaceutical ingredients. To request a sample copy / brochure of this report, please visit this https://www.rootsanalysis.com/reports/long-acting-drug-delivery-market/request-sample.html Lately, many technologies are being explored to develop long-acting drugs in various dosage formats, such as long-acting injectables, depot injections, implantable devices and combination products. The long-acting drug delivery technologies have come a long way with the inclusion of liposomes, microspheres and polymers for the fabrication of biodegradable and biocompatible delivery system. Apart from this, the interdependency of drug, excipient and release environment plays a crucial role to decide the release kinetics of the drug. Long-acting formulations are more patient compliant, in terms of sharp reduction in the dosing regimen. These drugs are administered infrequently (ranging from once weekly to yearly) owing to the prolonged drug release after a single shot. The technological advancements for the long-acting profile of the drugs (small molecules, peptides, biologics) have led to the rise in number of novel therapeutics in the market along with the growing number of long-acting molecules in the clinical development pipeline. Of late, the demand for the availability of long-acting vaginal rings as multipurpose prevention technologies for women is also surfacing. Further, the pharmaceutical industry is extensively focusing on the development of long-acting injectables for protein-based drugs and multidrug therapies. Moreover, the potential of long acting injectables is being explored in several debilitating chronic diseases, such as Alzheimer’s, Parkinson’s disease, blindness and HIV. Owing to the advanced LADD technologies, formulation and developmental challenges associated with these complex dosage forms, the reliability on the stakeholders having the expertise in this domain has upsurged. This will eventually aid the drug developers to address the bottlenecks stemming from conventional treatment options and improve the clinical outcome. For additional details, please visit https://www.rootsanalysis.com/reports/long-acting-drug-delivery-market.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Smart Labels Market: Industry Trends and Global Forecasts, 2022-2035 2. AI-based Digital Pathology / AI Pathology Market: Industry Trends and Global Forecasts, 2022-2035 About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com